Expand / Collapse search
Watch TV
☰

Quotes displayed in real-time or delayed by at least 15 minutes. Market data provided by Factset. Powered and implemented by FactSet Digital Solutions.  Legal Statement.

This material may not be published, broadcast, rewritten, or redistributed. ©2025 FOX News Network, LLC. All rights reserved. FAQ - New Privacy Policy

baxter international inc. - BAX

BAX

Close Chg Chg %
18.91 -0.43 -2.25%

Closed Market

18.48

-0.43 (2.25%)

Volume: 7.93M

Last Updated:

Dec 4, 2025, 4:00 PM EDT

Trade Now

Company Overview: baxter international inc. - BAX

BAX Key Data

Open

$18.81

 Day Range

18.33 - 18.93

52 Week Range

17.40 - 37.74

 Market Cap

$9.71B

Shares Outstanding

514.06M

 Public Float

511.85M

Beta

0.61

 Rev. Per Employee

N/A

P/E Ratio

N/A

 EPS

-$0.52

Yield

276.01%

 Dividend

$0.01

EX-DIVIDEND DATE

Nov 28, 2025

 SHORT INTEREST

N/A

AVERAGE VOLUME

8.55M

  

BAX Performance

1 Week
 
 0.80%
 
1 Month
 
 4.94%
 
3 Months
 
 -22.65%
 
1 Year
 
 -40.60%
 
5 Years
 
 -75.78%
 

BAX Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 20
Full Ratings ➔

About baxter international inc. - BAX

Baxter International, Inc. engages in the provision of a portfolio of essential healthcare products including acute and chronic dialysis therapies, sterile intravenous (IV) solutions, infusion systems and devices, parenteral nutrition therapies, inhaled anesthetics, generic injectable pharmaceuticals, surgical hemostat and sealant products, surgical equipment, smart bed systems, patient monitoring and diagnostic technologies, and respiratory health devices. It operates through the following segments: Americas, Europe, Middle East and Africa (EMEA), Asia-Pacific (APAC), and Hillrom. The Americas, EMEA, and APAC segments offer a portfolio of essential healthcare products. The Hillrom segment provides digital and connected care solutions and collaboration tools, including smart bed systems, patient monitoring and diagnostic technologies, respiratory health devices, and equipment for the surgical space. The company was founded by Davis Baxter in 1931 and is headquartered in Deerfield, IL.

BAX At a Glance

Baxter International, Inc.
One Baxter Parkway
Deerfield, Illinois 60015-4625
Phone 1-224-948-2000 Revenue 10.64B
Industry Medical Specialties Net Income -649,000,000.00
Sector Health Technology Employees 38,000
Fiscal Year-end 12 / 2025
View SEC Filings

BAX Valuation

P/E Current N/A
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) N/A
Price to Sales Ratio 1.398
Price to Book Ratio 2.139
Price to Cash Flow Ratio 14.59
Enterprise Value to EBITDA 15.804
Enterprise Value to Sales 2.502
Total Debt to Enterprise Value 0.505

BAX Efficiency

Revenue/Employee 279,894.737
Income Per Employee -17,078.947
Receivables Turnover 6.148
Total Asset Turnover 0.394

BAX Liquidity

Current Ratio 1.36
Quick Ratio 1.045
Cash Ratio 0.271

BAX Profitability

Gross Margin 36.235
Operating Margin 6.459
Pretax Margin -2.717
Net Margin -6.102
Return on Assets -1.247
Return on Equity -4.386
Return on Total Capital -1.651
Return on Invested Capital -1.795

BAX Capital Structure

Total Debt to Total Equity 193.122
Total Debt to Total Capital 65.884
Total Debt to Total Assets 52.164
Long-Term Debt to Equity 152.455
Long-Term Debt to Total Capital 52.011
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Baxter International Inc. - BAX

Collapse All in section
All values USD millions. 2021 2022 2023 2024 5-year trend
Sales/Revenue
12.78B 15.11B 14.81B 10.64B
Sales Growth
+9.52% +18.22% -1.99% -28.20%
Cost of Goods Sold (COGS) incl D&A
7.56B 9.88B 9.23B 6.78B
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
890.00M 1.40B 1.26B 997.00M
Depreciation
592.00M 650.00M 611.00M 372.00M
Amortization of Intangibles
298.00M 753.00M 652.00M 625.00M
COGS Growth
+8.10% +30.66% -6.63% -26.51%
Gross Income
5.22B 5.23B 5.58B 3.85B
Gross Income Growth
+11.63% +0.19% +6.79% -30.99%
Gross Profit Margin
+40.83% +34.61% +37.70% +36.24%
2021 2022 2023 2024 5-year trend
SG&A Expense
3.14B 3.93B 3.98B 3.17B
Research & Development
529.00M 602.00M 655.00M 510.00M
Other SG&A
2.61B 3.32B 3.33B 2.66B
SGA Growth
+9.83% +25.07% +1.50% -20.53%
Other Operating Expense
- - - (2.00M)
-
Unusual Expense
446.00M 3.21B 1.09B 711.00M
EBIT after Unusual Expense
1.64B (1.90B) 507.00M (24.00M)
Non Operating Income/Expense
(8.00M) (28.00M) (92.00M) 137.00M
Non-Operating Interest Income
14.00M 20.00M 70.00M 67.00M
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
152.00M 421.00M 518.00M 402.00M
Interest Expense Growth
- +176.97% +23.04% -22.39%
Gross Interest Expense
163.00M 432.00M 533.00M 415.00M
Interest Capitalized
11.00M 11.00M 15.00M 13.00M
Pretax Income
1.48B (2.35B) (103.00M) (289.00M)
Pretax Income Growth
+14.32% -259.31% +95.62% -180.58%
Pretax Margin
+11.55% -15.57% -0.70% -2.72%
Income Tax
182.00M 68.00M (34.00M) 37.00M
Income Tax - Current - Domestic
(1.00M) 7.00M 6.00M 40.00M
Income Tax - Current - Foreign
329.00M 286.00M 459.00M 259.00M
Income Tax - Deferred - Domestic
(111.00M) (305.00M) (387.00M) (218.00M)
Income Tax - Deferred - Foreign
(35.00M) 80.00M (112.00M) (44.00M)
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
1.29B (2.42B) (69.00M) (326.00M)
Minority Interest Expense
11.00M 12.00M 7.00M 11.00M
Net Income
1.28B (2.43B) (76.00M) (337.00M)
Net Income Growth
+16.52% -289.49% +96.88% -343.42%
Net Margin Growth
+10.04% -16.10% -0.51% -3.17%
Extraordinaries & Discontinued Operations
- - (150.00M) (312.00M)
-
Discontinued Operations
- - (150.00M) (312.00M)
-
Net Income After Extraordinaries
1.28B (2.43B) (226.00M) (649.00M)
Preferred Dividends
- - - -
-
Net Income Available to Common
1.28B (2.43B) (226.00M) (649.00M)
EPS (Basic)
2.5578 -4.8274 -0.4466 -1.2726
EPS (Basic) Growth
+18.14% -288.73% +90.75% -184.95%
Basic Shares Outstanding
502.00M 504.00M 506.00M 510.00M
EPS (Diluted)
2.5276 -4.8274 -0.4466 -1.2726
EPS (Diluted) Growth
+18.58% -290.99% +90.75% -184.95%
Diluted Shares Outstanding
508.00M 504.00M 506.00M 510.00M
EBITDA
2.97B 2.71B 2.86B 1.68B
EBITDA Growth
+12.57% -8.95% +5.76% -41.18%
EBITDA Margin
+23.26% +17.91% +19.33% +15.83%

Snapshot

Average Recommendation HOLD Average Target Price 22.615
Number of Ratings 20 Current Quarters Estimate 0.535
FY Report Date 12 / 2025 Current Year's Estimate 2.365
Last Quarter’s Earnings 0.69 Median PE on CY Estimate N/A
Year Ago Earnings 1.89 Next Fiscal Year Estimate 2.289
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 13 8 14 14
Mean Estimate 0.53 0.48 2.36 2.29
High Estimates 0.56 0.57 2.39 2.43
Low Estimate 0.52 0.40 2.35 2.00
Coefficient of Variance 2.79 11.97 0.58 5.83

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 2 2 3
OVERWEIGHT 2 2 2
HOLD 14 14 12
UNDERWEIGHT 1 1 1
SELL 1 1 1
MEAN Hold Hold Hold

Insider Actions for Baxter International Inc. - BAX

Date Name Shares Transaction Value
Mar 11, 2025 Alok Sonig EVP,Group President,Pharma 100,332 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $35.44 per share 3,555,766.08
Mar 11, 2025 David S. Rosenbloom EVP and General Counsel 104,780 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $35.44 per share 3,713,403.20
Mar 11, 2025 Heather Knight EVP, Chief Operating Officer 118,934 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 11, 2025 Heather Knight EVP, Chief Operating Officer 177,362 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 11, 2025 Heather Knight EVP, Chief Operating Officer 141,688 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $35.44 per share 5,021,422.72
Mar 11, 2025 Reaz Rasul EVP,Group Pres,Healthcare 87,417 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 11, 2025 Reaz Rasul EVP,Group Pres,Healthcare 124,614 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 11, 2025 Reaz Rasul EVP,Group Pres,Healthcare 98,394 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $35.44 per share 3,487,083.36
Mar 11, 2025 Anita A. Zielinski SVP, CAO and Controller 17,123 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 11, 2025 Alok Sonig EVP,Group President,Pharma 99,905 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 11, 2025 Alok Sonig EVP,Group President,Pharma 130,298 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 11, 2025 Jeanne K. Mason EVP, Chief HR Officer 183,963 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $35.44 per share 6,519,648.72
Mar 11, 2025 David S. Rosenbloom EVP and General Counsel 58,873 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 11, 2025 Joel Todd Grade EVP and CFO 98,478 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 11, 2025 Joel Todd Grade EVP and CFO 118,434 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 11, 2025 Joel Todd Grade EVP and CFO 88,896 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $35.44 per share 3,150,474.24
Mar 11, 2025 James W. Borzi EVP,Chief Supply Chain Officer 33,302 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 11, 2025 James W. Borzi EVP,Chief Supply Chain Officer 73,134 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 11, 2025 James W. Borzi EVP,Chief Supply Chain Officer 63,145 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $35.44 per share 2,237,858.80
Mar 11, 2025 Jeanne K. Mason EVP, Chief HR Officer 52,331 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00

Baxter International Inc. in the News